研究設計理論 ( 一 ): RANDOMIZED TRIALS. 醫學研究初階課程 General Medicine, CGMH 劉素旬醫師 03/12/2013
|
|
- Alberta Lindsey
- 5 years ago
- Views:
Transcription
1 1 研究設計理論 ( 一 ): RANDOMIZED TRIALS 醫學研究初階課程 General Medicine, CGMH 劉素旬醫師 03/12/2013
2 2 Learning Objectives Definition of a trial Features of trial design Elements of a trial Purposes of randomization and masking Reason for analysis by intention to treat Ethical issues Reporting guideline
3 3 What is a Trial? The action or process of putting something to a test or proof (Webster) An experiment designed and carried out to provide information on the merits of one treatment or procedure relative to another (Prof. Meinert C. )
4 4 Definitions for Clinical Trial A controlled experiment having a clinical event as an outcome measure, done in a clinical setting, and involving persons having a specific disease or health condition (Prof. Meinert) A controlled experiment to evaluate the efficacy and safety of a treatment. (Prof. Meinert)
5 5 Why Are Clinical Trials Important? (I) Gateway for new medical advances Gold standard for evaluation Drugs, devices, management Guideline for medical care Insurance coverage EBM
6 6 Why Are Clinical Trials Important? (II) Economic impact Costs of medical treatments Important segment of the economy Ethical issues Human subject experiments Best use of limited resources Access to information
7 7 Epidemiologic Studies Measuring Descriptive Diseases Health behaviors Environmental exposures Health-related costs Comparative Examining associations between exposures and health outcomes Group comparison Relative measures of disease
8 8 Alternatives to A Randomized Trial Without a comparison group Case report Case series With a comparison group Historical controls Simultaneous, nonrandomized controls Pre- post design
9 9 Essence of a Trial Design Experimentation (vs. observation) Exposure is under the control of the investigator Randomized Non-randomized Exposure is merely observed by the investigator in observational studies Method for allocating exposure/intervention Prospective standardized protocol Innovation or efficacy of the intervention is unknown
10 Source: care.diabetesjournals.org 10
11 Source: clincancerres.aacrjournals.org 11
12 12 Before The Need for A Trial Source:
13 Source: 13
14 14 Phases of Clinical Trials for Evaluation of New Drugs Phase I Clinical pharmacology Optimum dose, toxicity, PK, PD (usually healthy volunteers or patients, not controlled) Phase II Clinical investigation Safety and efficacy, sometimes controlled (usually patients) Phase III Clinical trial Comparative efficacy, expanded and controlled usually randomized Phase IV Post-marketing trials Adverse effects or off-label use, controlled observational studies or uncontrolled post-marketing surveillance
15 15 Efficacy vs. effectiveness Efficacy Trial To assess the efficacy of a treatment under ideal conditions Trial setting not designed or intended to approximate everyday conditions Effectiveness Trial To assess usefulness of a test treatment Trial conditions approximate everyday practice conditions
16 16 Types of Controls No therapy Trial of removal of allergens from home environment to control asthma Placebo Use of estrogen vs. placebo for heart disease prevention in women Sham procedure Acupuncture vs. incorrect placement of needles Standard treatment Sequential anti-h. pylori treatment vs. standard treatment
17 17 Types of Trial Designs Parallel comparison Cross-over Factorial Group allocation (cluster randomized trial)
18 18 Parallel Randomized Trial Source:
19 19 Cross-over Trial Each subject serves as his/her own control Feasible only if there is no carry-over treatment effect after the washout period Cannot exam for treatment effect on mortality If order of treatments may influence results, treatment administration can be randomized
20 20 Factorial Design Two rationales Potential economical way to test two treatments simultaneously, if their modes of action are independent Method to test for treatment synergy Source: Abernethy et al. Contemp Clin Trial 2006; 27(1):83-100
21 21 Factorial Design: Two Factors Source: Arnold et al. Simulation methods to estimate design power: an overview for applied research BMC Med Res Methodol
22 22 Cluster Randomization Trial Randomization unit is a group of individuals When individual randomization and intervention is not feasible or acceptable Tracking Contamination Administrative resources Outcomes and analysis must be appropriate to group allocation design Group measures of outcome Individual measures, accounting for correlation
23 23 Group Allocation (Cluster Randomization) Source: Arnold et al. Simulation methods to estimate design power: an overview for applied research BMC Med Res Methodol
24 24 Treatment Comparisons Depending on the alternative hypothesis Superiority trials: one treatment is better than the other Two sided: H a : A > B or A < B One sided: H a : A > B; H a : A < B Equivalence trials: two treatments are clinically equivalent (within some acceptable small margin) Two sided: H a : A B or A B Non-inferiority trials: one treatment is as effective as the other One sides: H a : A B
25 25 Interventions That Can Be Evaluated Treatments, including drugs and cognitive behavioral therapy Preventive measures Screening programs Vaccination Personal protective equipment Health service delivery or technology Individual vs. group intervention
26 26 Target Population People with a disease People at high risk for a disease/condition Primary prevention Secondary prevention General population Primary prevention Health care delivery program Community health program
27 27 Types of outcome Intervention Health outcomes: mortality, other clinical event rate, disease-free survival, biomarker, quality of life, cost Prevention Incidence of disease, mortality Health care delivery Health outcomes, process outcomes Community health: Indices of population health
28 28 Follow-up Length Short-term: often use surrogate outcome, biomarker Long-term: clinical event End of observation After a defined period of time A common close-out date (administrative censoring)
29 29 Scale of A Trial Single-center Multi-center International
30 30 Elements in the Design of Randomized Controlled Trials (RCT) 1. Selection of subjects 2. Allocation of subjects to treatment groups 3. Data collection 4. Masking 5. Data analysis
31 31 1.Selection of Subjects Representativeness Generalizability (external validity)
32 32 2.Allocation of subjects Predictable assignment (not recommended) Day of the week Birth date Order enrolled Randomization Not predictable Having no specific pattern; lack causal relationship Process in which there is associated with every legitimate outcome a probability
33 33 Goal of Randomization To compare otherwise similar groups by removing potential biases in the choice of treatment(s) Selection bias Factors associated with prognosis Treatment Outcome Confounding by indication Main reason why RCT is considered gold standard of study design
34 34 Goal of Randomization Secondary: to increase the likelihood of balanced groups in known and unknown risk factors Tertiary: to provide a probability basis for hypothesis testing, i.e. to assure statistical tests will have valid significance levels
35 35 Results of a Trial of BCG Vaccine Non-randomized controls No. Cases No. TB Death % Vaccinated Controls Randomized controls No. Cases No. TB Death % Vaccinated Controls
36 36 Observational Study Intervention Arm N=1000 Control Arm N= Total Deaths 300 Mortality: 180/1000 =18% 300/1000=30%
37 37 Observational Study Intervention Arm N=1000 IRHB (-) IRHB(+) N=800 N=200 Control Arm N=1000 IRHB (-) IRHB(+) N=500 N= Total Deaths 300 Mortality: 180/1000 =18% 300/1000=30% Proportions of patients with arrhythmia in the two comparison groups may differ
38 38 A Randomized Trial Intervention Arm N=1000 IRHB (-) IRHB(+) N=654 N=346 Control Arm N=1000 IRHB (-) IRHB(+) N=649 N= Total Deaths 241 Mortality: 238/1000 =23.8% 241/1000=24.1% P-value= Proportions of patients with arrhythmia in the two comparison groups may differ
39 39 Take a break Illustration: Cathy Wilcox
40 40 2. Allocation of Subjects Types of Randomization Schemes Simple randomization Restricted randomization Blocking Stratification Adaptive randomization
41 41 Simple Randomization Table of random numbers
42 42 Simple Randomization Scheme An Example If 2 groups are compared When digit is: 0-4 Assignment is Treatment A When digit is: 5-9 Assignment is Treatment B If digit is If 3 groups are compared Next assignment is 1-3 Treatment A 4-6 Treatment B 7-9 Treatment C 0 is ignored
43 43 Simple Randomization Computer randomization schemes Create lists of random numbers Generate treatment assignment Provide reproducible audit trail of treatment assignment Control and keep records of access to treatment assignment Source:
44 44 Simple Randomization Advantages Complete independence among each assignment Completely unpredictable Numbers of patients assigned to each group should be equal in the long run Disadvantages Imbalances when sample size is not large enough Numbers of patients in each group Confounding factor Lower power Diminish credibility of results
45 45 Restricted Randomization Randomization with constraints to produce expected assignment ratio according to time or specified covariate(s) Permuted block or blocking Stratification
46 46 Blocking Choose the smallest possible block size The sum of integers defined in the treatment allocation ratio Examples: 2 for a 1:1 ratio; 3 for a 2:1 ratio Larger block sizes are multiples of the smallest one: 4, 6, 8, List all possible block sequences (permutations) Example: for a block size of 4 with a 1:1 treatment allocation ratio BAAB ABAB BBAA ABBA.
47 47 Blocking (cont.) Randomly choose one block with replacement until the desired number of assignments Randomly order blocks to create the assignment list Source: bmsi.ru
48 48 Blocking Advantages Overall balance, esp. in smaller trials Achieve balance periodically Protects against timerelated changes Good statistical power Disadvantages Can facilitate prediction of future assignment More problematic for unmasked trials or poorly masked trials Remedy#1: block size(s) remains a secret Remedy#2: use more than one block size
49 49 Stratification 1. Stratify by Sex 1000 Patients 600 Males 400 Females 2. Stratify by Age 360 Adults (<65 yrs) 240 Elderly ( 65 yrs) 300 Adults (<65 yrs) 100 Elderly ( 65 yrs) 3. Randomize each subgroup Treatment A =500 Treatment B =500
50 50 Stratification To ensure balance in treatment assignments within subgroups defined before randomization Subgroup should be related to outcome Essentially create separate treatment assignment schemes for each stratum
51 51 Practicalities of Stratification Limit to a few variables Typical ones Clinic in a multicenter trial Surgeon Stage of disease Demographic characteristics (age, gender) Too many strata may lead to overall imbalances Must use blocking to ensure that stratification is effective Strata can be varying sizes
52 52 Stratification and Blocking Source: Morrissey et al Contemp Clin Trials
53 53 Adaptive Randomization The probability of assignment to treatment groups does not remain constant but depends on the current balance or composition of the groups (Piantadosi, 1997)
54 54 Covariate-Adaptive Randomization Minimization After randomizing the first patient, the treatment assignment that yields the smallest imbalance is chosen Balance marginal treatment totals across prognostic factors Can handle many more factors than stratification Allocation sequence cannot be determined in advance
55 55 Response-Adaptive Randomization Play the winner Change allocation ratio to favor the better treatment based on the primary outcome Need to evaluate outcome (or surrogate outcome) relatively quickly Source: Gupta et al J Clin Epidemiol
56 56 Misconceptions about Randomization Haphazard procedure is the same Guarantees comparable groups Guarantees that actual treatment allocations will match allocation ratio A study without randomization is invalid
57 57 Randomization Does Not Assure external validity Eligibility criteria Actual patient population Real-world conditions Eliminate bias associated with data collection, treatment adherence or follow-up
58 58 Generalizability of Randomized Clinical Trials A.k.a external validity May not provide good estimates of the absolute effect of treatment for the general population However, relative treatment effect may be generalizable to the general population
59 59 3.Data Collection Treatment Compliance Outcome Prognostic profile at entry Baseline characteristics
60 60 4.Masking Treatment assignment Subjects Primary physicians of study subjects Data collectors (evaluators) Data analyst Outcome assessment More important if treatment assignment is not masked
61 61 Level of Masking Single - participant Double - participant AND investigator Triple - participant AND investigator AND monitoring committee Source: scientific-misconduct.blogspot.com
62 62 Masking Protects Against Bias in Reports and behavior of participants Investigator s bias Data collection Outcome assessment Concomitant treatments
63 63 5.Data Analysis Problems of non-compliance Unplanned cross-overs: drop-outs, drop-ins Example: National Emphysema Treatment Trial (NETT), Source: JHSPH OpenCourseWare
64 64 5.Data Analysis Intention-totreat analysis: net effect of noncompliance will reduce the observed difference Source: jama.jamanetwork.com
65 65 5.Data Analysis Secondary: Per-protocol (As-treated) analysis Observational in nature
66 66 Compliance Analyses Coronary Drug Project 5-year Mortality No. Patients Mortality Clofibrate % Placebo % Source: Canner et al. 1980
67 67 Compliance Analyses Coronary Drug Project 5-year Mortality No. Patients Mortality Clofibrate Arm % Poor complier (<80%) Good complier ( 80%) % % Placebo Arm % Source: Canner et al. 1980
68 68 Compliance Analyses Coronary Drug Project 5-year Mortality Clofibrate group Placebo group Compliance No. Patients Mortality No. Patients Mortality Poor complier (<80%) Good complier ( 80%) % % % % Total % % Source: Canner et al. 1980
69 69 Dealing with Non-compliance Use of pilot studies (run-in periods), however, effectiveness depends on Precision in predicting compliance Costs of recruitment Monitoring compliance Interview, pill-counting Medication bottle devices Blood/urine tests Directly observed treatment (DOT)
70 70 5.Data Analysis Subgroup analysis Lack of power Over-interpretation Screening questions to help decide if a subgroup analysis is justified Was the analysis a priori defined at the design phase? Is the analysis subject to bias? Is the analysis biologically plausible? Is the result of the trial significant overall?
71 71 5.Data Analysis: Expressing Results of Randomized Trials Efficacy Relative risk (RR)- the ratio of rates of outcomes comparing treatment and control groups RR = Rate in treatment gruop Rate in control group
72 72 5.Data Analysis: Expressing Results of Randomized Trials Efficacy Relative risk reduction (RRR)- the proportional reduction in rates of outcomes comparing treatment and control groups RRR = Rate in control group Rate in treatment group Rate in control group = ARR Baseline rate = 1 RR * Absolute risk reduction
73 73 5.Data Analysis: Expressing Results of Randomized Trials Number needed to treat (NNT) Number of patients who would have to be treated in order to prevent one event of outcome NNT = 1 ARR Number needed to harm (NNH) Number of patients who could be harmed in order to prevent one event of outcome NNH = 1 ARI * Absolute risk increase (in adverse events of therapy)
74 74 Ethical Issues Is it ethical to randomize? Or not to randomize? Can truly informed consent be obtained? Who should elicit consent? When can placebo be used? When can shame procedures be used? When should a trial be stopped earlier than planned?
75 75 Equipoise Genuine uncertainty regarding the comparative therapeutic merits of each intervention being tested Theoretical equipoise: evidence of benefits of each treatment is well balanced Clinical equipoise: no consensus within the expert clinical community Individual vs. collective equipoise
76 76 Reporting Guideline CONSORT for clinical trials Enrollment CONSORT 2010 Flow Diagram Assessed for eligibility (n= ) Excluded (n= ) Not meeting inclusion criteria (n= ) Declined to participate (n= ) Other reasons (n= ) Randomized (n= ) Allocated to intervention (n= ) Received allocated intervention (n= ) Did not receive allocated intervention (give reasons) (n= ) Allocation Allocated to intervention (n= ) Received allocated intervention (n= ) Did not receive allocated intervention (give reasons) (n= ) Lost to follow-up (give reasons) (n= ) Discontinued intervention (give reasons) (n= ) Follow-Up Lost to follow-up (give reasons) (n= ) Discontinued intervention (give reasons) (n= ) Analysed (n= ) Excluded from analysis (give reasons) (n= ) Analysis Analysed (n= ) Excluded from analysis (give reasons) (n= ) Source:
77 Source: 77
78 78 THANK YOU FOR YOUR ATTENTION Next on 4/9/2013 研究設計理論 ( 二 ): Cohort Study
Issues to Consider in the Design of Randomized Controlled Trials
Issues to Consider in the Design of Randomized Controlled Trials Jay Wilkinson, MD, MPH Professor of Pediatrics & Epidemiology Miller School of Medicine Seminar Purpose To facilitate an interactive discussion
More informationRandomized Controlled Trial
Randomized Controlled Trial Training Course in Sexual and Reproductive Health Research Geneva 2016 Dr Khalifa Elmusharaf MBBS, PgDip, FRSPH, PHD Senior Lecturer in Public Health Graduate Entry Medical
More informationIn this second module in the clinical trials series, we will focus on design considerations for Phase III clinical trials. Phase III clinical trials
In this second module in the clinical trials series, we will focus on design considerations for Phase III clinical trials. Phase III clinical trials are comparative, large scale studies that typically
More informationCHL 5225 H Advanced Statistical Methods for Clinical Trials. CHL 5225 H The Language of Clinical Trials
CHL 5225 H Advanced Statistical Methods for Clinical Trials Two sources for course material 1. Electronic blackboard required readings 2. www.andywillan.com/chl5225h code of conduct course outline schedule
More informationStatistics for Clinical Trials: Basics of Phase III Trial Design
Statistics for Clinical Trials: Basics of Phase III Trial Design Gary M. Clark, Ph.D. Vice President Biostatistics & Data Management Array BioPharma Inc. Boulder, Colorado USA NCIC Clinical Trials Group
More informationCONSORT 2010 checklist of information to include when reporting a randomised trial*
CONSORT 2010 checklist of information to include when reporting a randomised trial* Section/Topic Title and abstract Introduction Background and objectives Item No Checklist item 1a Identification as a
More informationGlossary. Ó 2010 John Wiley & Sons, Ltd
Glossary The majority of the definitions within this glossary are based on, but are only a selection from, the comprehensive list provided by Day (2007) in the Dictionary of Clinical Trials. We have added
More informationEBM: Therapy. Thunyarat Anothaisintawee, M.D., Ph.D. Department of Family Medicine, Ramathibodi Hospital, Mahidol University
EBM: Therapy Thunyarat Anothaisintawee, M.D., Ph.D. Department of Family Medicine, Ramathibodi Hospital, Mahidol University How to appraise therapy literature Are the result valid? What are the result?
More informationCritical Appraisal Series
Definition for therapeutic study Terms Definitions Study design section Observational descriptive studies Observational analytical studies Experimental studies Pragmatic trial Cluster trial Researcher
More informationIssues in Randomization
INTRODUCTION TO THE PRINCIPLES AND PRACTICE OF CLINICAL RESEARCH Issues in Randomization Paul Wakim, PhD Chief, Biostatistics and Clinical Epidemiology Service Clinical Center, National Institutes of Health
More informationAP Statistics Exam Review: Strand 2: Sampling and Experimentation Date:
AP Statistics NAME: Exam Review: Strand 2: Sampling and Experimentation Date: Block: II. Sampling and Experimentation: Planning and conducting a study (10%-15%) Data must be collected according to a well-developed
More informationRandomized Clinical Trials
Randomized Clinical Trials p. 1/42 Randomized Clinical Trials Hematology/Oncology Lecture Series Elizabeth G. Hill, PhD Associate Professor of Biostatistics 17 November 2011 Randomized Clinical Trials
More informationGLOSSARY OF GENERAL TERMS
GLOSSARY OF GENERAL TERMS Absolute risk reduction Absolute risk reduction (ARR) is the difference between the event rate in the control group (CER) and the event rate in the treated group (EER). ARR =
More informationGreg Pond Ph.D., P.Stat.
Statistics for Clinical Trials: Basics of a Phase III Trial Design Greg Pond Ph.D., P.Stat. Ontario Clinical Oncology Group Escarpment Cancer Research Institute Department of Oncology, McMaster University
More informationThe RoB 2.0 tool (individually randomized, cross-over trials)
The RoB 2.0 tool (individually randomized, cross-over trials) Study design Randomized parallel group trial Cluster-randomized trial Randomized cross-over or other matched design Specify which outcome is
More informationExperimental Design. Terminology. Chusak Okascharoen, MD, PhD September 19 th, Experimental study Clinical trial Randomized controlled trial
Experimental Design Chusak Okascharoen, MD, PhD September 19 th, 2016 Terminology Experimental study Clinical trial Randomized controlled trial 1 PHASES OF CLINICAL TRIALS Phase I: First-time-in-man studies
More informationClinical Epidemiology for the uninitiated
Clinical epidemiologist have one foot in clinical care and the other in clinical practice research. As clinical epidemiologists we apply a wide array of scientific principles, strategies and tactics to
More informationStudy design continued: intervention studies. Outline. Repetition principal approaches. Gustaf Edgren, PhD Karolinska Institutet.
Study design continued: intervention studies Gustaf Edgren, PhD Karolinska Institutet Background Outline Uncontrolled trials Non randomized, controlled trials Randomized controlled trials (with an overview
More informationGuidelines for Reporting Non-Randomised Studies
Revised and edited by Renatus Ziegler B.C. Reeves a W. Gaus b a Department of Public Health and Policy, London School of Hygiene and Tropical Medicine, Great Britain b Biometrie und Medizinische Dokumentation,
More informationClinical Trials. Susan G. Fisher, Ph.D. Dept. of Clinical Sciences
Clinical Trials Susan G. Fisher, Ph.D. Dept. of Clinical Sciences When to Do a RCT Exposure of interest is modifiable and individuals are willing to relinquish control Legitimate uncertainty exists about
More informationexposure/intervention
Kathleen A. Kennedy, MD, MPH University of Texas Medical School at Houston Medical School Most clinical research evaluates an association between exposure/intervention outcome. 1 Does the investigator
More informationAre the likely benefits worth the potential harms and costs? From McMaster EBCP Workshop/Duke University Medical Center
CRITICAL REVIEW FORM FOR THERAPY STUDY Did experimental and control groups begin the study with a similar prognosis? Were patients randomized? Was randomization concealed? Were patients analyzed in the
More informationLecture 4. Analytical Interventional Studies
Lecture 4 Analytical Interventional Studies By the end of this lecture the student will be able to : Identify the concept of analytical Interventional studies Identify the concept of clinical trials and
More informationPhase III Clinical Trial. Randomization, Blinding and Baseline Assessment. Chi-hong Tseng, PhD Statistics Core, Department of Medicine
Phase III Clinical Trial Randomization, Blinding and Baseline Assessment Chi-hong Tseng, PhD Statistics Core, Department of Medicine Reference Clinical Trials: A Practical Approach. Pocock SJ. Wiley, Chichester,
More informationSpecial Features of Randomized Controlled Trials
Special Features of Randomized Controlled Trials Bangkok 2006 Kenneth F. Schulz, PhD, MBA Critical Methodological Elements in RCTs Randomization Avoiding and handling exclusions after trial entry Blinding
More informationDelfini Evidence Tool Kit
General 1. Who is sponsoring and funding the study? What are the affiliations of the authors? Study Design Assessment Internal Validity Assessment Considerations: This can be helpful information and is
More informationResearch Methodology Workshop. Study Type
Research Methodology Workshop Study Type What type of question? Frequency: how common is it? Aetiology: What caused this? Intervention: Does this intervention work? Diagnosis or test evaluation: How accurate
More informationOverview of Clinical Study Design Laura Lee Johnson, Ph.D. Statistician National Center for Complementary and Alternative Medicine US National
Overview of Clinical Study Design Laura Lee Johnson, Ph.D. Statistician National Center for Complementary and Alternative Medicine US National Institutes of Health 2012 How Many Taken a similar course
More informationCase-ControlControl. None
Study Designs & Methodologies (w/ /M Measures of Association) What is the most useful and appropriate study design? Larry W. Segars, PharmD, DrPH, FCCP, FACE, BCPS, RPh Associate Dean College of Biosciences
More informationRecent developments for combining evidence within evidence streams: bias-adjusted meta-analysis
EFSA/EBTC Colloquium, 25 October 2017 Recent developments for combining evidence within evidence streams: bias-adjusted meta-analysis Julian Higgins University of Bristol 1 Introduction to concepts Standard
More informationSequence balance minimisation: minimising with unequal treatment allocations
Madurasinghe Trials (2017) 18:207 DOI 10.1186/s13063-017-1942-3 METHODOLOGY Open Access Sequence balance minimisation: minimising with unequal treatment allocations Vichithranie W. Madurasinghe Abstract
More informationDepartment of OUTCOMES RESEARCH
Department of OUTCOMES RESEARCH Clinical Research Design Sources of Error Types of Clinical Research Randomized Trials! Daniel I. Sessler, M.D. Professor and Chair Department of OUTCOMES RESEARCH The Cleveland
More informationDesign and analysis of clinical trials
Design and analysis of clinical trials Lecture 3 1.Basic Design Considerations 2.Sample Size determinationa 3.Randomization 2018-01-31 Previous Lectures Definition of a clinical trial The drug development
More informationExperimental and Quasi-Experimental designs
External Validity Internal Validity NSG 687 Experimental and Quasi-Experimental designs True experimental designs are characterized by three "criteria for causality." These are: 1) The cause (independent
More informationEvidence Informed Practice Online Learning Module Glossary
Term Abstract Associations Attrition Bias Background and Significance Baseline Basic Science Bias Blinding Definition An abstract is a summary of a research article. It usually includes the purpose, methods,
More informationModule 5. The Epidemiological Basis of Randomised Controlled Trials. Landon Myer School of Public Health & Family Medicine, University of Cape Town
Module 5 The Epidemiological Basis of Randomised Controlled Trials Landon Myer School of Public Health & Family Medicine, University of Cape Town Introduction The Randomised Controlled Trial (RCT) is the
More informationLecture 2. Key Concepts in Clinical Research
Lecture 2 Key Concepts in Clinical Research Outline Key Statistical Concepts Bias and Variability Type I Error and Power Confounding and Interaction Statistical Difference vs Clinical Difference One-sided
More informationBIOSTATISTICAL METHODS
BIOSTATISTICAL METHODS FOR TRANSLATIONAL & CLINICAL RESEARCH PROPENSITY SCORE Confounding Definition: A situation in which the effect or association between an exposure (a predictor or risk factor) and
More informationCRITICAL APPRAISAL OF MEDICAL LITERATURE. Samuel Iff ISPM Bern
CRITICAL APPRAISAL OF MEDICAL LITERATURE Samuel Iff ISPM Bern siff@ispm.unibe.ch Contents Study designs Asking good questions Pitfalls in clinical studies How to assess validity (RCT) Conclusion Step-by-step
More informationRandomization: Too Important to Gamble with
Randomization: Too Important to Gamble with A Presentation for the Delaware Chapter of the ASA Oct 18, 2012 Dennis Sweitzer, Ph.D., Principal Biostatistician Medidata Randomization Center of Excellence
More informationEvaluating Social Programs Course: Evaluation Glossary (Sources: 3ie and The World Bank)
Evaluating Social Programs Course: Evaluation Glossary (Sources: 3ie and The World Bank) Attribution The extent to which the observed change in outcome is the result of the intervention, having allowed
More informationPhD Course in Biostatistics
PhD Course in Biostatistics Univ.-Prof. DI Dr. Andrea Berghold Institute for Medical Informatics, Statistics and Documentation Medical University of Graz andrea.berghold@medunigraz.at Content Introduction
More informationClinical Study Design: From Pilot to Randomized Controlled Trials
Clinical Study Design: From Pilot to Randomized Controlled Trials Thomas C. Hulsey, MSPH, Sc.D. Professor and Chair, Department of Epidemiology Director, Clinical Research Education, CTSI What is a clinical
More informationTitle 1 Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym
SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents* Section/item Item No Description Addressed on page number Administrative information Title 1 Descriptive
More informationGlossary From Running Randomized Evaluations: A Practical Guide, by Rachel Glennerster and Kudzai Takavarasha
Glossary From Running Randomized Evaluations: A Practical Guide, by Rachel Glennerster and Kudzai Takavarasha attrition: When data are missing because we are unable to measure the outcomes of some of the
More informationClinical problems and choice of study designs
Evidence Based Dentistry Clinical problems and choice of study designs Asbjørn Jokstad University of Oslo, Norway Nov 21 2001 1 Manipulation with intervention Yes Experimental study No Non-experimental
More informationEvidence Based Practice
Evidence Based Practice RCS 6740 7/26/04 Evidence Based Practice: Definitions Evidence based practice is the integration of the best available external clinical evidence from systematic research with individual
More informationIntervention vs. Observational Trials:
Intervention vs. Observational Trials: A Brief Introduction Introduction Just like an architect translates a vision for a building into blueprints, so an investigator translates their research idea into
More informationCLINICAL PROTOCOL DEVELOPMENT
CLINICAL PROTOCOL DEVELOPMENT Clinical Protocol (1) Background/Justification --Where we are in the field --What the study will add that is important Objectives --Primary hypothesis --Secondary hypotheses
More informationCHECK-LISTS AND Tools DR F. R E Z A E I DR E. G H A D E R I K U R D I S TA N U N I V E R S I T Y O F M E D I C A L S C I E N C E S
CHECK-LISTS AND Tools DR F. R E Z A E I DR E. G H A D E R I K U R D I S TA N U N I V E R S I T Y O F M E D I C A L S C I E N C E S What is critical appraisal? Critical appraisal is the assessment of evidence
More informationStructural Approach to Bias in Meta-analyses
Original Article Received 26 July 2011, Revised 22 November 2011, Accepted 12 December 2011 Published online 2 February 2012 in Wiley Online Library (wileyonlinelibrary.com) DOI: 10.1002/jrsm.52 Structural
More informationGlossary of Practical Epidemiology Concepts
Glossary of Practical Epidemiology Concepts - 2009 Adapted from the McMaster EBCP Workshop 2003, McMaster University, Hamilton, Ont. Note that open access to the much of the materials used in the Epi-546
More information4/10/2018. Choosing a study design to answer a specific research question. Importance of study design. Types of study design. Types of study design
Choosing a study design to answer a specific research question Importance of study design Will determine how you collect, analyse and interpret your data Helps you decide what resources you need Impact
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) POINTS TO CONSIDER ON MISSING DATA
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 15 November 2001 CPMP/EWP/1776/99 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) POINTS TO
More informationProtocol Development: The Guiding Light of Any Clinical Study
Protocol Development: The Guiding Light of Any Clinical Study Susan G. Fisher, Ph.D. Chair, Department of Clinical Sciences 1 Introduction Importance/ relevance/ gaps in knowledge Specific purpose of the
More informationWATCHMAN PROTECT AF Study Rev. 6
WATCHMAN PROTECT AF Study Rev. 6 Protocol Synopsis Title WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients with Atrial Fibrillation (PROTECT AF) Sponsor Atritech/Boston Scientific
More informationTORCH: Salmeterol and Fluticasone Propionate and Survival in COPD
TORCH: and Propionate and Survival in COPD April 19, 2007 Justin Lee Pharmacy Resident University Health Network Outline Overview of COPD Pathophysiology Pharmacological Treatment Overview of the TORCH
More informationTrial designs fully integrating biomarker information for the evaluation of treatment-effect mechanisms in stratified medicine
Trial designs fully integrating biomarker information for the evaluation of treatment-effect mechanisms in stratified medicine Dr Richard Emsley Centre for Biostatistics, Institute of Population Health,
More informationDetails on the procedure and devices used for assessment and calculation of
SUPPLEMENTAL METHODS Details on the procedure and devices used for assessment and calculation of cardiovascular parameters The peripheral psychophysiological activation was registered via impedance cardiography
More informationCritical Review Form Therapy Objectives: Methods:
Critical Review Form Therapy Clinical Trial Comparing Primary Coronary Angioplasty with Tissue-Plasminogen Activator for Acute Myocardial Infarction (GUSTO-IIb), NEJM 1997; 336: 1621-1628 Objectives: To
More informationHow to Interpret a Clinical Trial Result
How to Interpret a Clinical Trial Result Edward V. Loftus, Jr., M.D. Professor of Medicine Division of Gastroenterology and Hepatology Mayo Clinic College of Medicine Rochester MN CP123456-1 Are results
More informationEvaluating and Interpreting Clinical Trials
Article #2 CE Evaluating and Interpreting Clinical Trials Dorothy Cimino Brown, DVM, DACVS University of Pennsylvania ABSTRACT: For the practicing veterinarian, selecting the best treatment for patients
More informationPubH 7405: REGRESSION ANALYSIS. Propensity Score
PubH 7405: REGRESSION ANALYSIS Propensity Score INTRODUCTION: There is a growing interest in using observational (or nonrandomized) studies to estimate the effects of treatments on outcomes. In observational
More informationRANDOMIZED CLINICAL TRIALS. Study Designs. Randomized Clinical Trials (RCT) ASSIGN EXPOSURE Follow up Check for OUTCOME. Experimental studies
RANDOMIZED CLINICAL TRIALS Study Designs Observational studies Analytic studies Descriptive studies Randomized Controlled trials Case control Cohort Cross sectional Randomized Clinical Trials (RCT) Assign
More informationEvidence-based practice tutorial Critical Appraisal Skills
Evidence-based practice tutorial Critical Appraisal Skills Earlier evidence based practice tutorials have focussed on skills to search various useful sites on the internet for evidence. Anyone who has
More informationOverview. Goals of Interpretation. Methodology. Reasons to Read and Evaluate
Overview Critical Literature Evaluation and Biostatistics Ahl Ashley N. Lewis, PharmD, BCPS Clinical Specialist, Drug Information UNC Hospitals Background Review of basic statistics Statistical tests Clinical
More informationCONSORT 2010 Statement Annals Internal Medicine, 24 March History of CONSORT. CONSORT-Statement. Ji-Qian Fang. Inadequate reporting damages RCT
CONSORT-Statement Guideline for Reporting Clinical Trial Ji-Qian Fang School of Public Health Sun Yat-Sen University Inadequate reporting damages RCT The whole of medicine depends on the transparent reporting
More informationObservational Study Designs. Review. Today. Measures of disease occurrence. Cohort Studies
Observational Study Designs Denise Boudreau, PhD Center for Health Studies Group Health Cooperative Today Review cohort studies Case-control studies Design Identifying cases and controls Measuring exposure
More informationThursday, April 25, 13. Intervention Studies
Intervention Studies Outline Introduction Advantages and disadvantages Avoidance of bias Parallel group studies Cross-over studies 2 Introduction Intervention study, or clinical trial, is an experiment
More informationThe comparison or control group may be allocated a placebo intervention, an alternative real intervention or no intervention at all.
1. RANDOMISED CONTROLLED TRIALS (Treatment studies) (Relevant JAMA User s Guides, Numbers IIA & B: references (3,4) Introduction: The most valid study design for assessing the effectiveness (both the benefits
More informationOutline. What is Evidence-Based Practice? EVIDENCE-BASED PRACTICE. What EBP is Not:
Evidence Based Practice Primer Outline Evidence Based Practice (EBP) EBP overview and process Formulating clinical questions (PICO) Searching for EB answers Trial design Critical appraisal Assessing the
More information1. Draft checklist for judging on quality of animal studies (Van der Worp et al., 2010)
Appendix C Quality appraisal tools (QATs) 1. Draft checklist for judging on quality of animal studies (Van der Worp et al., 2010) 2. NICE Checklist for qualitative studies (2012) 3. The Critical Appraisal
More informationINTERPRETATION OF STUDY FINDINGS: PART I. Julie E. Buring, ScD Harvard School of Public Health Boston, MA
INTERPRETATION OF STUDY FINDINGS: PART I Julie E. Buring, ScD Harvard School of Public Health Boston, MA Drawing Conclusions TRUTH IN THE UNIVERSE Infer TRUTH IN THE STUDY Infer FINDINGS IN THE STUDY Designing
More informationChallenges of Observational and Retrospective Studies
Challenges of Observational and Retrospective Studies Kyoungmi Kim, Ph.D. March 8, 2017 This seminar is jointly supported by the following NIH-funded centers: Background There are several methods in which
More informationGRADE. Grading of Recommendations Assessment, Development and Evaluation. British Association of Dermatologists April 2018
GRADE Grading of Recommendations Assessment, Development and Evaluation British Association of Dermatologists April 2018 Previous grading system Level of evidence Strength of recommendation Level of evidence
More informationAppraising the Literature Overview of Study Designs
Chapter 5 Appraising the Literature Overview of Study Designs Barbara M. Sullivan, PhD Department of Research, NUHS Jerrilyn A. Cambron, PhD, DC Department of Researach, NUHS EBP@NUHS Ch 5 - Overview of
More informationAdaptive Randomization:
: Promise with Problems Russell W. Helms, Ph.D. Rho, Inc. Chapel Hill, NC RHelms@RhoWorld.com www.rhoworld.com Presented to The Annual DIA Workshop on Statistical Methodology in the Biopharmaceutical Sciences
More informationA NEW TRIAL DESIGN FULLY INTEGRATING BIOMARKER INFORMATION FOR THE EVALUATION OF TREATMENT-EFFECT MECHANISMS IN PERSONALISED MEDICINE
A NEW TRIAL DESIGN FULLY INTEGRATING BIOMARKER INFORMATION FOR THE EVALUATION OF TREATMENT-EFFECT MECHANISMS IN PERSONALISED MEDICINE Dr Richard Emsley Centre for Biostatistics, Institute of Population
More informationCONSORT 2010 checklist of information to include when reporting a randomised trial*
Supplemental Figures for: Ramosetron Versus Ondansetron in Combination with Aprepitant and Dexamethasone for the Prevention of Highly Emetogenic Chemotherapy-induced Nausea and Vomiting: A Multicenter,
More informationReal-world data in pragmatic trials
Real-world data in pragmatic trials Harold C. Sox,MD The Patient-Centered Outcomes Research Institute Washington, DC Presenter Disclosure Information In compliance with the accrediting board policies,
More informationClinical Evidence: Asking the Question and Understanding the Answer. Keeping Up to Date. Keeping Up to Date
Clinical Evidence: Asking the Question and Understanding the Answer Keeping Up to Date 5,000? per day 1,500 per day 95 per day Keeping Up to Date 5,000? per day 1,500 per day 95 per day 1 Bias Bias refers
More informationVocabulary. Bias. Blinding. Block. Cluster sample
Bias Blinding Block Census Cluster sample Confounding Control group Convenience sample Designs Experiment Experimental units Factor Level Any systematic failure of a sampling method to represent its population
More informationDepartment of International Health
JOHNS HOPKINS U N I V E R S I T Y Center for Clinical Trials Department of Biostatistics Department of Epidemiology Department of International Health Memorandum Department of Medicine Department of Ophthalmology
More informationCOURSE 4: STUDY DESIGN II: PHASE III TRIALS & ETHICAL ISSUES
COURSE 4: STUDY DESIGN II: PHASE III TRIALS & ETHICAL ISSUES PHASE III TRIAL DESIGNS...44 Randomized Controlled Clinical Trials (Parallel Design)...44 Uncontrolled Trials (Single Treatment)...47 Trials
More informationEBM, Study Design and Numbers. David Frankfurter, MD Professor OB/GYN The George Washington University
EBM, Study Design and Numbers David Frankfurter, MD Professor OB/GYN The George Washington University 1978? 1978 Best Picture of 1978 The Deer Hunter Universal Studios The 50th Academy Awards were held
More informationCritical Appraisal. Dave Abbott Senior Medicines Information Pharmacist
Critical Appraisal Dave Abbott Senior Medicines Information Pharmacist Aims Identify key components of clinical trial design and apply these to a critical appraisal of the literature Be able to work out
More informationFundamental Clinical Trial Design
Design, Monitoring, and Analysis of Clinical Trials Session 1 Overview and Introduction Overview Scott S. Emerson, M.D., Ph.D. Professor of Biostatistics, University of Washington February 17-19, 2003
More informationEffectiveness guidance document (EGD) for acupuncture research - a consensus document for conducting trials
Witt et al. BMC Complementary and Alternative Medicine 2012, 12:148 CORRESPONDENCE Open Access Effectiveness guidance document (EGD) for acupuncture research - a consensus document for conducting trials
More informationComplier Average Causal Effect (CACE)
Complier Average Causal Effect (CACE) Booil Jo Stanford University Methodological Advancement Meeting Innovative Directions in Estimating Impact Office of Planning, Research & Evaluation Administration
More informationStudy Designs. Randomized Clinical Trials (RCT) RCT: Example 1. RCT: Two by Two Table. Outcome. Exposure. Yes a b No c d
Study Designs Randomized Clinical Trials (RCT) Assign Exposure Randomly Experimental studies Analytic studies Observational studies Descriptive studies POPULATION Population People without the outcome
More informationBIOSTATISTICAL METHODS
BIOSTATISTICAL METHODS FOR TRANSLATIONAL & CLINICAL RESEARCH Designs on Micro Scale: DESIGNING CLINICAL RESEARCH THE ANATOMY & PHYSIOLOGY OF CLINICAL RESEARCH We form or evaluate a research or research
More informationConducting and managing randomised controlled trials (RCTs)
Conducting and managing randomised controlled trials (RCTs) Introduction Study Design We often wish to investigate the efficacy of new treatments and interventions on patient outcomes In this session,
More informationA re-randomisation design for clinical trials
Kahan et al. BMC Medical Research Methodology (2015) 15:96 DOI 10.1186/s12874-015-0082-2 RESEARCH ARTICLE Open Access A re-randomisation design for clinical trials Brennan C Kahan 1*, Andrew B Forbes 2,
More informationUpdates in Therapeutics 2015: The Pharmacotherapy Preparatory Review & Recertification Course
Updates in Therapeutics 2015: The Pharmacotherapy Preparatory Review & Recertification Course Study Designs: Fundamentals and Interpretation Kevin M. Sowinski, Pharm.D., FCCP Purdue University, College
More informationPlanning Sample Size for Randomized Evaluations.
Planning Sample Size for Randomized Evaluations www.povertyactionlab.org Planning Sample Size for Randomized Evaluations General question: How large does the sample need to be to credibly detect a given
More informationMath 140 Introductory Statistics
Math 140 Introductory Statistics Professor Silvia Fernández Sample surveys and experiments Most of what we ve done so far is data exploration ways to uncover, display, and describe patterns in data. Unfortunately,
More informationTrial Designs. Professor Peter Cameron
Trial Designs Professor Peter Cameron OVERVIEW Review of Observational methods Principles of experimental design applied to observational studies Population Selection Looking for bias Inference Analysis
More informationLecture Outline. Biost 590: Statistical Consulting. Stages of Scientific Studies. Scientific Method
Biost 590: Statistical Consulting Statistical Classification of Scientific Studies; Approach to Consulting Lecture Outline Statistical Classification of Scientific Studies Statistical Tasks Approach to
More informationGeneralizing the right question, which is?
Generalizing RCT results to broader populations IOM Workshop Washington, DC, April 25, 2013 Generalizing the right question, which is? Miguel A. Hernán Harvard School of Public Health Observational studies
More informationCritical Appraisal of RCT
Critical Appraisal of RCT What is critical appraisal? Definition Process of systematically examining research evidence to assess its reliability (validity/internal validity), results and relevance (external
More information